Alumis (ALMS) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategy

• Focused on precision immunology with two clinical TYK2 inhibitor assets and an undisclosed pipeline.

• Lead program envudeucitinib targets plaque psoriasis and lupus, with NDA filing planned for Q4 this year.

• Capital allocation decisions hinge on further data analysis and regulatory feedback, especially for SLE.

• Partnership opportunities are being actively explored to maximize value across multiple indications.

• Vision includes developing TYK2 inhibitors for a broad range of autoimmune diseases.

Clinical trial results and learnings

• Envudeucitinib showed strong efficacy and quality of life improvements in plaque psoriasis, with PASI 100 rates up to 55% at 48 weeks.

• Phase II-B lupus trial did not meet primary endpoints due to high placebo response in IFN-negative patients, but robust response seen in IFN-positive subgroup.

• Future lupus studies may focus on IFN-positive populations, pending regulatory feedback by year-end.

• Safety profile remains strong, with no major malignancy or JAK-like risks observed.

• A brain-penetrant TYK2 inhibitor (A-005) is planned for a Parkinson's biomarker study in 2027.

Regulatory and commercial plans

• NDA for envudeucitinib in plaque psoriasis targeted for Q4, with additional data to be presented at EADV.

• Labeling strategy aims for a clean label without JAK class warnings, leveraging strong safety data.

• Monitoring competitor launches and real-world performance to inform commercial strategy.

• Working on once-daily (QD) formulation to address market preference over BID dosing.

• Partnership discussions are ongoing, with timing considered favorable post-lupus data release.